Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 1 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Miromatrix Medical Inc. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 4 distinct examiners, indicating a broad spread of oversight despite the concentration of work within 1 distinct art unit. The focus in 1 distinct art unit suggests a highly specialized technological niche within the broader biotech sector. This concentration allows the applicant to develop a deep understanding of the specific examination trends within that unit.
GU, QINHUA is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Because the 4 pending office actions are split among 4 distinct examiners, the workload is evenly distributed across the individuals assigned to these cases. Practitioners should prepare for consistent examination standards across the portfolio given the single art unit involved. The presence of 4 distinct examiners for only 4 pending office actions means that each case is receiving a unique perspective, which may lead to varied outcomes despite the shared art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GU, QINHUA | 1 | 75.9% | +27.8% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| ESPERON, NATHAN GREGORY | 1 | 41.0% | +23.3% |
| BRIDGES, DONAVAN LEE | 1 | — | — |
| EBBINGHAUS, BRIANA NOEL | 1 | 61.6% | +63.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | — |
| 18680248 | Methods and Uses of Differentiated Cells | KASAYAN, KATRIEL BARCELLANO | — |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | — |
| 18702784 | SYSTEM FOR SUPPORTING BIOLOGICALLY ENGINEERED ORGANS | BRIDGES, DONAVAN LEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17440914 | Improved Decellularization of Isolated Organs | EBBINGHAUS, BRIANA NOEL | 71d |
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | — |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18759375 | Manufacturing of Bioengineered Recellularized Organs and Methods of Use Thereof | GU, QINHUA | — | §103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18680248 | Methods and Uses of Differentiated Cells | KASAYAN, KATRIEL BARCELLANO | — | §103§112 | Non-Final OA | — | Pending | May 31, 2024 |
| 18702789 | EXTRACORPOREAL ORGAN SUPPORT SYSTEM | ESPERON, NATHAN GREGORY | — | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18702784 | SYSTEM FOR SUPPORTING BIOLOGICALLY ENGINEERED ORGANS | BRIDGES, DONAVAN LEE | — | §102§103Other | Non-Final OA | — | Pending | Apr 18, 2024 |
| 17440914 | Improved Decellularization of Isolated Organs | EBBINGHAUS, BRIANA NOEL | 1632 | §103 | Final Rejection | 71d | Pending | Sep 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial